Awareness and Experience of using off-label Drugs by Doctors and Pharmacists in Libya
DOI:
https://doi.org/10.14738/bjhr.1205.19441Keywords:
Off-label Prescribing, OLDU, Off-label promotion, Patient SafetyAbstract
Background: The off-label use refers to the administration of an authorized medicinal product in a manner not specified in its official labeling. This practice raises significant legal, ethical, and safety concerns, particularly given its widespread prevalence. However, many healthcare professionals have limited awareness of the definition, scope, and clinical implications of off-label drug use. This study aimed to assess the knowledge and perceptions of pharmacists and physicians regarding off-label drug use in Libya. Methods: A prospective, questionnaire-based cross-sectional study was conducted among doctors and pharmacists in Libya. A total of 374 licensed Libyan healthcare professionals were targeted between September 2024 and March 2025. Results: 160 participants were included in the final analysis. Most respondents were female (n=106, 66%), with pharmacists and clinical pharmacists constituting the majority (37% and 23%, respectively). Additionally, 131 participants (82%) were affiliated with tertiary care settings, and most had 1-4 years of work experience (n=110, 69%). Only 69 respondents (44%) were aware of the correct definition of off-label drugs, particularly pharmacists and clinical pharmacists (p=0.02 and p=0.002, respectively). Off-label prescriptions were reported by 63 respondents (43%), with a higher prevalence among males (p=0.002). A significant proportion of participants were unaware of any institutional or national policies regarding off- label prescribing (64% and 72%, respectively). Concerns about the efficacy and safety of off-label prescribing were prevalent (61% and 68%, respectively). Notably, 62% of respondents reported encountering adverse drug reactions related to off-label prescriptions. Furthermore, 131 participants (82%) emphasized the importance of pharmacist involvement in off-label drug use decisions. Conclusion: These findings underscore the need for targeted educational interventions and formal regulatory guidelines to promote safer prescribing practices and improve patient outcomes, particularly among physicians engaged in off-label drug use.
References
C. M. Wittich, C. M. Burkle, and W. L. Lanier, “Ten common questions (and their answers) about off-label drug use,” Mayo Clin. Proc., vol. 87, no. 10, pp. 982–990, 2012, doi: 10.1016/j.mayocp.2012.04.017.
M. Mei, H. Xu, L. Wang, G. Huang, Y. Gui, and X. Zhang, “Current practice and awareness of pediatric off-label drug use in Shanghai, China-a questionnaire-based study,” BMC Pediatr., vol. 19, no. 1, pp. 1–7, 2019, doi: 10.1186/s12887-019-1664-7.
M. Drenska, E. Naseva, and I. Getov, “Physician’s knowledge and experience with the off-label use of medicines,” Biotechnol. Biotechnol. Equip., vol. 35, no. 1, pp. 111–116, 2021, doi: 10.1080/13102818.2020.1856718.
D. Alyami, A. A. Alyami, A. Alhossan, and M. Salah, “Awareness and Views of Pharmacists and Physicians Toward Prescribing of Drugs for Off-Label Use in the Pediatric Population in Saudi Arabia,” Cureus, vol. 14, no. 3, pp. 11–14, 2022, doi: 10.7759/cureus.23082.
S. Conroy et al., “Survey of unlicensed and off label drug use in paediatric wards in European countries,” Br. Med. J., vol. 320, no. 7227, pp. 79–82, Jan. 2000, doi: 10.1136/BMJ.320.7227.79.
D. Zanon et al., “Off-label prescribing patterns of antiemetics in children: A multicenter study in Italy,” Eur. J. Pediatr., vol. 172, no. 3, pp. 361–367, Mar. 2013, doi: 10.1007/S00431-012-1894-2.
C. Pandolfini and M. Bonati, “A literature review on off-label drug use in children,” Eur. J. Pediatr., vol. 164, no. 9, pp. 552–558, Aug. 2005, doi: 10.1007/S00431-005-1698-8.
J. Emmerich, N. Dumarcet, and A. Lorence, “France’s new framework for regulating off-label drug use,” N. Engl. J. Med., vol. 367, no. 14, pp. 1279–1281, Oct. 2012, doi: 10.1056/NEJMP1208347.
J. K. Aronson and R. E. Ferner, “Unlicensed and off-label uses of medicines: definitions and clarification of terminology,” Br. J. Clin. Pharmacol., vol. 83, no. 12, pp. 2615–2625, 2017, doi: 10.1111/bcp.13394.
K. A. Neville et al., “Off-label use of drugs in children,” Pediatrics, vol. 133, no. 3, pp. 563–567, 2014, doi: 10.1542/PEDS.2013-4060.
C. Lee Ventola, “Off-label drug information: Regulation, distribution, evaluation, and related controversies,” P T, vol. 34, no. 8, 2009.
A. S. Kesselheim, S. Woloshin, Z. Lu, F. A. Tessema, K. M. Ross, and L. M. Schwartz, “Physicians’ Perspectives on FDA Approval Standards and Off-label Drug Marketing,” JAMA Intern. Med., vol. 179, no. 5, pp. 707–709, May 2019, doi: 10.1001/JAMAINTERNMED.2018.8121.
N. Ghinea, I. Kerridge, M. Little, and W. Lipworth, “Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of ‘off-label’ prescribing,” J. Eval. Clin. Pract., vol. 23, no. 3, pp. 574–581, Jun. 2017, doi: 10.1111/JEP.12673.
“EudraLex - Volume 1 - European Commission.”
“CRS Search Results.”
“Federal Register :: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers; Revised Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request.”
S. A. Berns, E. S. Bulgakova, D. O. Orlov, and I. A. Belkin, “Assessment of Awareness and Experience of Using off-label Drugs by Doctors of Clinical Specialties,” Kardiologiya, vol. 61, no. 5, pp. 41–50, 2021, doi: 10.18087/CARDIO.2021.5.N1510.
W. F. Friedman, M. J. Hirschklau, M. P. Printz, P. T. Pitlick, and S. E. Kirkpatrick, “Pharmacologic closure of patent ductus arteriosus in the premature infant,” N. Engl. J. Med., vol. 295, no. 10, pp. 526–529, Sep. 1976, doi: 10.1056/NEJM197609022951003.
M. E. Schram, R. J. Borgonjen, C. M. J. M. Bik, J. G. Van Der Schroeff, J. J. E. Van Everdingen, and P. I. Spuls, “Off- label use of azathioprine in dermatology: a systematic review,” Arch. Dermatol., vol. 147, no. 4, pp. 474–488, Apr. 2011, doi: 10.1001/ARCHDERMATOL.2011.79. 101
S. Berthet, B. Charpiat, and J. Y. Mabrut, “Erythromycin as a prokinetic agent: risk factors,” J. Visc. Surg., vol. 147, no. 2, 2010, doi: 10.1016/J.JVISCSURG.2010.06.001.
G. A. Kerchner, M. C. Tartaglia, and A. L. Boxer, “Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia,” Expert Rev. Neurother., vol. 11, no. 5, pp. 709–717, May 2011, doi: 10.1586/ERN.11.6.
A. Atia, “Pharmacovigilance in Libya: Current Status and Future Trends,” Indian J. Pharm. Pract., vol. 12, no. 4, pp. 267–269, Sep. 2019, doi: 10.5530/IJOPP.12.4.56.
S. M. Price, A. C. O’Donoghue, L. Rizzo, S. Sapru, and K. J. Aikin, “What influences healthcare providers’ prescribing decisions? Results from a national survey,” Res. Social Adm. Pharm., vol. 17, no. 10, pp. 1770–1779, Oct. 2021, doi: 10.1016/J.SAPHARM.2021.01.012.
R. Basak and D. J. McCaffrey, “Hospital pharmacists’ perceived beliefs and responsibilities in indicationbased off-label prescribing,” Int. J. Clin. Pharm., vol. 40, no. 1, pp. 36–40, Feb. 2018, doi: 10.1007/S11096-017-0567-7/METRICS.
G. Mudur, “Indian Medical Association wants off-label prescribing,” BMJ Br. Med. J., vol. 328, no. 7446, p. 974, 2004, doi: 10.1136/BMJ.328.7446.974-C.
J. E. Raubenheimer, P. H. Myburgh, and A. S. Bhagavathula, “Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface,” BMC Glob. public Heal., vol. 2, no. 1, p. 63, Sep. 2024, doi: 10.1186/S44263-024-00095-W.
“Trulicity & Weight Loss | HCP | Trulicity (dulaglutide).”
C. Corcoran and T. F. Jacobs, “Metformin,” Encycl. Biomed. Gerontol. Vol. 1-3, vol. 2, pp. V2-424-V2-432, Aug. 2023, doi: 10.1016/B978-0-12-801238-3.62141-4.
D. C. Radley, S. N. Finkelstein, and R. S. Stafford, “Off-label prescribing among office-based physicians,” Arch. Intern. Med., vol. 166, no. 9, pp. 1021–1026, May 2006, doi: 10.1001/ARCHINTE.166.9.1021.
H. Chen, J. H. Reeves, J. E. Fincham, W. K. Kennedy, J. H. Dorfman, and B. C. Martin, “Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001,” J. Clin. Psychiatry, vol. 67, no. 6, pp. 972–982, 2006, doi: 10.4088/JCP.V67N0615.
H. W. Lin, K. Phan, and S. J. Lin, “Trends in off-label beta-blocker use: a secondary data analysis,” Clin. Ther.,
R. H. Dworkin et al., “Recommendations for the pharmacological management of neuropathic pain: an overview and literature update,” Mayo Clin. Proc., vol. 85, no. 3 Suppl, 2010, doi: 10.4065/MCP.2009.0649.
R. S. Stafford, “Regulating off-label drug use--rethinking the role of the FDA,” N. Engl. J. Med., vol. 358, no. 14, pp. 1427–1429, Apr. 2008, doi: 10.1056/NEJMP0802107.
S. Ekins-Daukes, P. J. Helms, M. W. Taylor, and J. S. McLay, “Off-label prescribing to children: attitudes and experience of general practitioners,” Br. J. Clin. Pharmacol., vol. 60, no. 2, pp. 145–149, Aug. 2005, doi: 10.1111/J.1365-2125.2005.02397.X.
S. K. Gupta and R. P. Nayak, “Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities,” J. Pharmacol. Pharmacother., vol. 5, no. 2, pp. 88–92, 2014, doi: 10.4103/0976-500X.130046/ASSET/BE14EA90-8B26-4204-81AA 302023C57AFC/ASSETS/0976-500X.130046.FP.PNG.
K. A. Neville et al., “Off-Label Use of Drugs in Children,” Pediatrics, vol. 133, no. 3, pp. 563–567, Mar. 2014, doi: 10.1542/PEDS.2013-4060.
G. Mudur, “Indian Medical Association wants off-label prescribing,” BMJ, vol. 328, no. 7446, p. 974, Apr. 2004, doi: 10.1136/BMJ.328.7446.974-C.
A. Vijay, J. E. Becker, and J. S. Ross, “Patterns and predictors of off-label prescription of psychiatric drugs,” PLoS One, vol. 13, no. 7, p. e0198363, Jul. 2018, doi: 10.1371/JOURNAL.PONE.0198363.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Monia Ramadan Taher, Riad Mohammed Abdelrahman, Mohsen Hussein Suleiman
This work is licensed under a Creative Commons Attribution 4.0 International License.
